This fast track antibody is not yet fully characterized. It is subject to these terms and conditions

ab31812 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab31812 は 4 報の論文で使用されています。

  • Ahmad K  et al. Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL. Oncogenesis 3:e127 (2014). ChIP . PubMed: 25402609
  • Wilkinson AC  et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep 3:116-27 (2013). WB, ChIP, CHIPseq ; Human . PubMed: 23352661
  • Geng H  et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov 2:1004-23 (2012). WB, ChIP, CHIPseq ; Human . PubMed: 23107779
  • Biswas D  et al. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci U S A 108:15751-6 (2011). WB ; Human . PubMed: 21896721

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"